Hello, you are using an old browser that's unsafe and no longer supported. Please consider
your browser to a newer version, or downloading a
Anna Krichevsky, Ph.D.
Brigham and Woman's Hospital
2009 Sontag Award Recipient
"The support of the Foundation was instrumental at the early stage of my career. I am truly grateful to Rick Sontag and the amazing team he was able to build for the opportunity to be exposed to great science and meet remarkable individuals that became my role models. Our basic research is now leading toward a clinical trial on GBM, the result I could not dream of only a few years ago, and that could not be achieved without the Sontag Foundation support."
About DSA-Funded Research
Only about 2% of the human genome encodes for proteins; the biomedical research was, nevertheless, until recently, almost exclusively focused on this tiny fraction of the genome. The majority of the human genome is transcribed to non-protein-coding RNA (ncRNA), which is often considered as the “dark matter” or junk material. However, ncRNAs play diverse regulatory roles and represent critical elements that make humans highly complex and distinct from other animals. These regulatory elements are essential for normal physiologic functions and frequently dysregulated in disease. The brain, the most complex of human organs, is characterized by the extreme number and diversity of ncRNA species. The Krichevsky Lab investigates various classes of ncRNA, such as microRNA, lncRNA, and enhancer RNA, involved in the pathogenesis of malignant brain tumors and neurodegenerative diseases. Her research ranges from understanding the basic biology of ncRNA to the development of novel ncRNA-targeting therapeutic strategies for neurologic diseases.
Associate Professor of Neurology/Neurobiology, Brigham and Women’s Hospital, Harvard Medical School
Second Moscow Medical School, Russia, B.S., Medical and Biological Sciences
Hebrew University of Jerusalem, Israel, M.S., Microbiology
Hebrew University of Jerusalem, Israel, Ph.D., Microbiology